This article is more than 5 years old. Information may no longer be current.
Psoriasis guidelines top December's dermatology news
Click Here to Manage Email Alerts
The establishment of defined treatment targets for patients with psoriasis was among the most-read articles in December on Healio.com/Dermatology.
Other widely read articles included the FDA’s approval of Eucrisa ointment to treat mild-to-moderate atopic dermatitis in patients aged 2 years and older:
New guidelines for psoriasis treatment goals established
Members of the National Psoriasis Foundation medical board established defined treatment targets for patients with psoriasis in a recent paper published in the Journal of the American Academy of Dermatology.
“This is a pivotal, groundbreaking effort that defines treatment targets for psoriasis patients in the U.S.,” April W. Armstrong, MD, MPH, National Psoriasis Foundation (NPF) member and dermatologist at of the Keck School of Medicine at University of Southern California, Los Angeles, stated in a press release. Read more
FDA approves Eucrisa for atopic dermatitis
The FDA announced it has approved Eucrisa ointment to treat mild-to-moderate atopic dermatitis in patients aged 2 years and older.
“Today’s approval provides another treatment option for patients dealing with mild-to-moderate atopic dermatitis,” Amy Egan, deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research, stated in a press release. Read more
New methods to evaluate wound healing reviewed
Although nontraditional methods have been developed to measure wound healing, there is no gold standard method for evaluation, according to a review article published in Dermatologic Surgery.
The authors from Thailand reviewed research on nontraditional techniques to evaluate wound healing, with the techniques divided into five categories based on their measured outcome. Read more
Radiofrequency effectively treats rosacea when compared with pulsed dye laser
Radiofrequency therapy was as effective as pulsed dye laser in treating rosacea, particularly in patients with papulopustular rosacea, according to published study results.
Researchers studied 30 patients with rosacea (19 women; average age, 43.4 years), including 20 patients with erythematotelangiectatic rosacea (ETR) and 10 patients with papulopustular rosacea (PPR). Read more
Momenta Pharmaceuticals announces efficacy for proposed biosimilar to Humira for psoriasis
Momenta Pharmaceuticals has announced results of a phase 3 clinical study of M923, a biosimilar Humira candidate, in patients with moderate-to-severe chronic psoriasis, which met its primary endpoint.
There was an equivalent proportion of patients in the study who achieved the primary endpoint of at least 75% reduction in psoriasis Area and Severity Index (PASI 75) following 16 weeks of treatment with M923 and Humira (adalimumab, AbbVie), according to a press release. Read more